$BMY News

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

BMY Gets Opdivo Label Expansion in the EU, Update on Camzyos

Assessing Bristol Myers Squibb (BMY) Valuation As Shares Track Mixed Returns And Earnings Outlook

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

Bristol Myers Squibb: This Pullback Is A Gift For Long-Term Investors

SystImmune And Bristol Myers Squibb Announce Sichuan Biokin Reports Results From Prespecified Interim Analyses Of Two Phase 3 Studies Evaluating Izalontamab Brengitecan

Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks

Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO

Bristol Myers Squibb Wins EU Green Light for Opdivo-Based Hodgkin Lymphoma Treatment (BMY)

Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

Full Transcript: Bristol-Myers Squibb Q1 2026 Earnings Call

Bristol Myers Squibb Says FDA Accepts Snda For Camzyos As Potential Treatment For Adolescents With Symptomatic oHCM; PDUFA Date Set September 30

Bristol Myers Squibb Announces European Commission Approval Of Opdivo In Combination With Doxorubicin, Vinblastine And Dacarbazine For The Treatment Of Adult And Adolescent Patients 12 Years Of Age And Older With Previously Untreated Stage III Or IV Classical Hodgkin Lymphoma

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks

How Bristol Is Building On Its $74 Billion Celgene Buyout With New 'Molecular Glue'

Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

Bistol Myers Squibb Announces Results From Its Phase 3 SUCCESSOR-2 Trial Of CELMoD Mezigdomide In Combination With Carfilzomib And Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma; Results Showed MeziKd Demonstrated Clinically Meaningful And Statistically Significant Improvement